Thursday, 6 August 2015
Specialty enzymes find immense application in therapeutics
Enzymes are proteins naturally produced by living organisms that stimulate and speed up bio-chemical reactions. These prove beneficial in building new cells, repairing damaged ones in the blood and tissues of organisms. As these are multifunctional and have high specificity, they find widespread applications in pharmaceutical industries, in diagnosing chronic diseases and in the treatment of various ailments including cancer, cardiovascular diseases and more. Several Industrial and household catalysis depends on the activity of enzymes as they lower activation energy and improve manufacturing efficiencies. Besides, they are cost effective and act as eco-friendly catalysts in various industrial, environmental and consumer products.
Specialty enzymes are proteins that are used in pharma, biotech & diagnostics, and act as biocatalysts in reaction, accelerating the pace of reactions thus acting as a cost-effective and eco-friendly entity in industrial and environmental products. Specialty enzymes find immense applications in areas such as molecular biology and creating molecules that have effective therapeutic uses. These enzymes are recommended by doctors to control incidences of digestive disorders, recent clinical trials point towards reliable evidences in being used as treatment therapy for diseases like cancer. Administered individually or with other treatments specialty enzymes such as prolactazyme, collagenase treats skin ulcer. Enzymes like asparaginase and streptokinase are used to treat various diseases. These enzymes are used in small amounts in therapeutics so that they do not cause any side effect. Furthermore, they must be highly purified and have a high degree of specificity. For instance alkaline phosphatase and peroxides are used in immunoassays.
Recently, researchers at the Centenary Institute in Sydney have uncovered new information about an enzyme called DPP9. They believe DPP9 is a potential therapeutic target and limits the growth of cancerous cells in liver. Currently, the molecule is highly powerful and needs to be externally regulated. Researches are also trying to ascertain how the cells of the body can achieve this naturally. Professor Mark Gorrell, who is behind the discovery of DPP9, is currently researching on the functionalities of the enzyme. There are other such endeavors undertaken by the research departments of prominent pharma industries and market analysts are observant of the growth dynamics of global specialty enzymes. Recently, a report by Allied Market Research titled “World Specialty Enzymes (Pharmaceuticals, Biotechnology R&D, Diagnostics)”. As per the report, specialty enzymes market for biotechnology research, pharmaceuticals and diagnostics was valued at $561.9 million in the year 2014 and would generate a revenue of $947.5 million by the end of 2020, growing at 9.4% CAGR amid the period 2015 - 2020.